Wells Fargo & Company Initiates Coverage on enGene (NASDAQ:ENGN)

Wells Fargo & Company assumed coverage on shares of enGene (NASDAQ:ENGN) in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $30.00 price objective on the stock.

A number of other research firms also recently commented on ENGN. SVB Leerink assumed coverage on shares of enGene in a research report on Tuesday, February 20th. They issued an outperform rating and a $31.00 target price on the stock. UBS Group began coverage on enGene in a report on Thursday, March 28th. They issued a buy rating and a $37.00 target price for the company. Morgan Stanley assumed coverage on enGene in a research note on Friday, March 8th. They set an overweight rating and a $40.00 price target on the stock. Leerink Partnrs reiterated an outperform rating on shares of enGene in a research note on Tuesday, February 20th. Finally, Guggenheim began coverage on shares of enGene in a report on Monday, April 15th. They issued a buy rating and a $34.00 target price on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $34.40.

enGene Stock Performance

Shares of enGene stock opened at $14.80 on Monday. enGene has a 52 week low of $6.69 and a 52 week high of $43.00. The company has a 50 day moving average of $16.11.

Insiders Place Their Bets

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the completion of the transaction, the insider now owns 3,036,153 shares in the company, valued at approximately $45,542,295. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Institutional Trading of enGene

A number of institutional investors have recently modified their holdings of the business. Fcpm Iii Services B.V. acquired a new stake in enGene in the fourth quarter valued at $80,097,000. Omega Fund Management LLC purchased a new position in shares of enGene in the 4th quarter valued at about $10,441,000. BVF Inc. IL acquired a new stake in shares of enGene in the fourth quarter valued at about $20,777,000. Finally, Vivo Capital LLC purchased a new stake in enGene during the fourth quarter worth about $6,264,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.